Heart failure in thyrotoxicosis, an approach to management

British Journal of Clinical Pharmacology

Volumn 46, Issue 5, 1998, Pages 421-424

  Choudhury, Robin P ^a,b   MacDermot, John ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CARBIMAZOLE; DIGOXIN; FUROSEMIDE; HEPARIN; PROPRANOLOL; WARFARIN;

ADRENERGIC SYSTEM; AGED; ARTICLE; CARDIOVERSION; CASE REPORT; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOEMBOLISM; THYROTOXICOSIS;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; AMIODARONE; ANTITHYROID AGENTS; CARBIMAZOLE; CARDIOTONIC AGENTS; DIGOXIN; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; THYROTOXICOSIS;

EID: 0031731156     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00804.x     Document Type: Article

References (50)

1. DeGroot WJ, Leonard JJ. Hyperthyroidism as a high cardiac output state. Am Heart J 1970; 79: 265-275.
2. Merillon JP, Passa PH, Chastre J, Wolf A, Gourgon R. Left ventricular function and hyperthyroidism. Br Heart J 1981; 46: 137-143.
3. Sandler G, Wilson GM. The nature and prognosis of heart disease in thyrotoxicosis. Q J Med 1959; 28: 247-269.
4. Summers VK, Surtees SJ. Thyrotoxicosis and heart disease. Acta Med Scand 1961; 169: 661-671.
5. Likoff WB, Levine SA. Thyrotoxicosis as the sole cause of heart failure. Am J Med Sci 1943; 206: 425-434.
6. Shlesinger P, Beachimol AB. The pure form of thyrotoxic heart disease: a clinical and pathological study. Am J Cardiol 1958; 2: 430-440.
7. Forfar JC, Muir AL, Sawyers SA, Toft AD. Abnormal left ventricular function in hyperthyroidism. Evidence for a reversible cardiomyopathy. N Engl J Med 1982; 307: 1165-1170.
8. Ikram H. The nature and prognosis of thyrotoxic heart disease. Q J Med 1985; 54: 19-28.
9. Gustafson TA, Bahl JJ, Markham BE, Roeske WR, Morkin E. Hormonal regulation of myosin heavy chain and a actin gene expression in cultured fetal rat heart myocytes. J Biol Chem 1987; 262: 13316-13322.
10. 2+ ATPase in the rat heart. J Biol Chem 1988; 263: 6941-6944.
11. Fagg Sanford C, Griffin E, Wildenthal K. Synthesis and degradation of myocardial protein during the development and regression of thyroxine induced cardiac hypertrophy in rats. Circ Res 1978; 43: 688-694.
12. Mintz G, Pizzarello R, Klein I. Enhanced left ventricular diastolic function in hyperthyroidism: non-invasive assessment and response to treatment. J Clin Endocrinol Metab 1991; 73: 146-150.
13. Sachs RN, Vignot M, Modigliani E, et al. Absence de lesoins histologiques ulstrastructurales du myocarde dans l'insuffisance cardiaque de l'hyperthyoidie. Ann Med Intern (Paris) 1986; 137: 375-378.
14. Levey GS, Klein I. Catecholamine-thyroid hormone interactions and the cardiovascular manifestations of hyperthyroidism. Am J Med 1990; 88: 642-646.
15. Coulombe P, Dussault JH, Walker P. Plasma catecholamine concentration in hyperthyroidism and hypothyroidism. Metabolism 1976; 25: 973-978.
16. Bayliss RIS, Edwards OM. Urinary excretion of free catecholamines in graves' disease. Endocrinol 1971; 49: 167-173.
17. Williams LT, Lefkowitz RJ, Watanbe AM, et al. Thyroid hormone regulation of β-adrenergic number. J Biol Chem 1977; 252: 2787-2789.
18. Liggett SB, Shah SD, Cayer PE. Increased fat and skeletal muscle β-adrenergic receptors but unaltered metabolic and hemodynamic sensitivity to epinephrine in vivo in experimental human thyrotoxicosis. J Clin Invest 1989; 83: 803-809.
19. Okada F, Ide H, Hata S, Honma M, Ui M. Plasma cyclic nucleotide responses to insulin induced hypoglycaemia and metecholine in patients with hyperthyroidism. Eur J Clin Invest 1980; 10: 81-86.
20. Levey GS. Catecholamine sensitivity, thyroid hormone and the heart. Am J Med 1971; 50: 413-420.
21. Bar-Sela S, Ehrenfeld M, Eliakim M. Arterial embolism in thyrotoxicosis with atrial fibrillation. Arch Int Med 1981; 141: 1191-1192.
22. Yuen RWH, Gutteridge DH, Thompson PL, Robinson JS. Embolism in thyrotoxic atrial fibrillation. Med J Austr 1979; 1: 630-631.
23. Ostrander LD, Brandt RL, Kjelsberg MO, Epstein FH. Electrocardiographic findings among the adult population of a total natural community, Tecumseh, Michigan. Circulation 1965; 31: 888-898.
24. Freedberg AS, Papp JG, Vaughan Williams EM. The effect altered thyroid state on atrial intracellular potentials. J Physiol (Lond) 1970; 207: 357-369.
25. Staffurth JS, Gibberd MC, Tang Fui SNG. Arterial embolism in thyrotoxicosis with atrial fibrillation. Br Med J 1977; (2): 688-690.
26. Boston area anticoagulation trial for atrial fibrillation investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-1511.
27. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with non rheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-1412.
28. Simone JV, Abildgaard CF, Schulman I. Blood coagulation in thyroid dysfunction. N Engl J Med 1965; 273: 1057-1061.
29. Channick BJ, Adlin EV, Marks AD, et al. Hyperthyroidism and mitral valve prolapse. New Engl J Med 1981; 305: 497-500.
30. Shenfield GM, Thompson J, Horn DB. Plasma and urinary digoxin in thyroid dysfunction. Eur J Clin Pharmacol 1977; 12: 437-443.
31. Chaudhury S, Ismail-Beigi F, Gick GG, Levenson R, Edelman IS. Effect of thyroid hormone on the abundance of Na,K adenosine triphosphate -subunit messenger ribonucleic acid. Mol Endocrinol 1987; 1: 83-89.
32. Geffner DL, Hershman JM. Beta-adrenergic blockade for the treatment of hyperthyroidisin. Am J Med 1992; 93: 61-68.
33. Hellman R, Kelly KL, Mason WD. Propranolol for thyroid storm. N Engl J Med 1977; 297: 671-672.
34. Ikram H. Haemodynamic effects of beta adrenergic blockade in hyperthyroid patients with and without heart failure. Br Med J 1977; (1): 1505-1507.
35. Isley WL, Dahl S, Gibbs H. Use of esmolol in managing a thyrotoxic patient needing emergency surgery. Am J Med 1990; 89: 122-123.
36. Barbier GH, Shettigar UR, Appunn DO. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol. Int J Clin Pharmacol Ther 1995; 33: 212-218.
37. Rubenfeld S, Silverman VE, Welch KMA, Mallette LE, Kohler PO. Variable plasma propranolol levels in thyrotoxicosis. N Engl J Med 1979; 300: 353-354.
38. Routledge PA, Shand DG. Clinical pharmacokonetics of propranolol. Clin Pharmacokinetic 1979; 4: 73-90.
39. Geffner DL, Sladek J, Hershman JM. Pharmacokinetics and clinical effects of atenolol therapy of hyperthyroidism. Drugs Exp Clin Res 1990; 16: 167-173.
40. Singh BN. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am J Cardiol 1996; 78: 41-53.
41. Galve E, Rius T, Ballester R, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 1996; 27: 1079-1082.
42. Tieleman RG, Gosselink AT, Crijns HJ, et al. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol 1997; 79: 53-57.
43. Cybulski J, Kulakowski P, Makowska E, Czepiel A, Sikora Frac M, Ceremuzynski L. Intravenous amiodarone is safe and seems to be effective in termination of paroxysmal supraventricular tachyarrhythmias. Clin Cardiol 1996; 19: 563-566.
44. Rao RH, McCready VR, Spathins GS. Iodine kinetic studies during amiodarone treament. J Clin Endocrinal Metab 1986; 62: 563-568.
45. Albert SG, Alves LE, Rose EP. Thyroid dysfunction during chronic amiodarone therapy. J Am Coll Cardiol 1987; 9: 175-183.
46. Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med 1997; 126: 63-73.
47. Perret G, Yin YL, Nicolas P, et al. Amiodarone decreases cardiac beta-adrenoceptors through an antagonistic effect on 3,5,3'triodothyronine. J Cardiovasc Pharmacol 1992;; 19: 541-545.
48. Unger J, Mavroudakis N, Lipski A, van Coevorden A. Treatment of supraventricular tachyarrhythmias associated with hyperthyroidism by radioiodine, amiodarone and propylthiouracil. Thyroidol 1991; 3: 85-88.
49. Van Reeth O, Unger J. Effects of amiodarone on serum T3 and T4 concentrations in hyperthyroid patients treated with propylthiouracil. Thyroid 1991; 1: 301-306.
50. Shenfield GM. Influence of thyroid dysfunction on drug pharmacokinetics. Clin Pharmacokinet 1981; 6: 275-297.